表紙
市場調查報告書
商品編碼
914626

Frontier Pharma:小細胞肺癌 (SCLC) - 多方面的創新藥物 (FIC:First in Class) 開發平台顯示侵佔性疾病的標靶治療藥的潛力

Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

出版日期: | 出版商: GlobalData | 英文 55 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供小細胞肺癌 (SCLC) 的創新藥物 (FIC:First in Class)的開發平台趨勢調查,小細胞肺癌的疾病概要,已上市醫藥品,各開發階段、分子類型、分子標的的開發平台趨勢,FIC、非FIC計劃比較,主要的分子標的趨勢,主要企業各種契約等資訊彙整。

第1章 目錄

第2章 小細胞肺癌:摘要整理

  • 顯示許多標靶治療藥的認證潛力的開發平台
  • 高標準的FIC革新
  • 緩解疾病藥物療法的需求

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
  • 階段分類
  • 革新的持續性
  • SCLC的流行病學
  • 已上市產品概要

第5章 開發平台評估

  • 概要
  • 開發平台:各開發階段、分子類型
  • 開發平台:各分子標的
  • 市場&開發平台計劃比較分佈:治療標的各系列
  • FIC、非FIC開發平台計劃比較分佈:各分子目標類別
    • FIC、非FIC開發平台計劃的比例
  • 對FIC分子標的FIC計劃的比例

第6章 FIC分子標的評估

  • 概要
  • 以GTPaseKRAS為目標的開發平台計劃
  • 以白細胞介素2受體β&伽馬為目標的開發平台計劃
  • 以熱休克蛋白質90為目標的開發平台計劃
  • 以絲胺酸/蘇氨酸蛋白激酶AKT (AKT1、AKT2、AKT3)為目標的開發平台計劃
  • 以A型肝炎病毒細胞受體2為目標的開發平台計劃
  • 以絲胺酸/蘇氨酸蛋白激酶ATR為目標的開發平台計劃
  • 以蛋白質磷酸酶2A為目標的開發平台計劃等

第7章 主要企業、各種契約

  • 概要
    • Allogene Therapeutics:Cellectis與許可證協定
    • Amgen、MD Anderson:在各種癌症類型聯盟協定
    • MabVax Therapeutics:Memorial Sloan Kettering Cancer Center和共同研究協定

第8章 附錄

目錄
Product Code: GDHC497FP

Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care (SOC) for several decades has been platinum-etoposide chemotherapy. Limited tumor tissue for translational research, poor understanding of the mechanisms underlying disease biology, and therapeutic resistance are major factors impeding the discovery of effective drugs, including targeted therapies in SCLC, proving a major clinical need for patients.

To date, there have been three targeted therapies approved to treat SCLC, Bristol-Myers Squibb's Opdivo (nivolumab), Roche's Tecentriq (atezolizumab), and Merck & Co.'s Keytruda (pembrolizumab) which were approved by the FDA in August 2018, March 2019 and June 2019, respectively. The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC. Following the approval of these new agents, relapsed/refractory patients are expected to have significantly improved therapeutic options. The increased prescription of branded therapies in treatment-naive and advanced patients will be the primary impetus driving the substantial growth in the SCLC market.

Scope:

  • There are 165 pipeline programs in active development for SCLC. What proportion of these products are first-in-class?
  • How does first-in-class innovation vary by development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class SCLC pipeline?
  • Which first-in-class targets have been identified as most promising for the treatment of SCLC?
  • How does the distribution of target classes differ in terms of development stage?
  • Across the SCLC landscape, there are 118 active companies. Which companies have formed partnerships?
  • Which companies have first-in-class assets in development with no prior deal involvement?

Reasons to buy:

  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SCLC market in terms of dominant molecule types and molecular targets.
  • Analyze and compare the SCLC pipeline and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class programs have been assessed and ranked according to their clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class pipeline programs for SCLC that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SCLC programs.

1 Table of Contents

2 Small Cell Lung Cancer: Executive Summary

  • 2.1 Pipeline Holds Some Potential for the Approval of More Targeted Therapies
  • 2.2 High Levels of First-in-Class Innovation
  • 2.3 Need for Disease-Modifying Pharmacotherapies

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Sustained Innovation in SCLC
  • 4.4 Epidemiology for SCLC
  • 4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

  • 5.1 Overview
  • 5.2 Pipeline by Stage of Development and Molecule Type
  • 5.3 Pipeline by Molecular Target
  • 5.4 Comparative Distribution of Programs Between SCLC Market and Pipeline by Therapeutic Target Family
  • 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
    • 5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
  • 5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline

6 First-in-Class Molecular Target Evaluation

  • 6.1 Overview
  • 6.2 Pipeline Programs Targeting GTPase KRAS
  • 6.3 Pipeline Programs Targeting Interleukin 2 Receptor Beta and Gamma
  • 6.4 Pipeline Programs Targeting Heat Shock Protein 90
  • 6.5 Pipeline Programs Targeting Serine/Threonine Protein Kinase AKT (AKT1, AKT2, AKT3)
  • 6.6 Pipeline Programs Targeting Hepatitis A Virus Cellular Receptor 2
  • 6.7 Pipeline Programs Targeting Serine/Threonine-Protein Kinase ATR
  • 6.8 Pipeline Programs Targeting Protein Phosphatase 2A
  • 6.9 Pipeline Programs Targeting Histone-lysine N-methyltransferase EZH2
  • 6.10 Pipeline Programs Targeting Lymphocyte Activation Gene 3 Protein

7 Key Players and Deals

  • 7.1 Overview
    • 7.1.1 Allogene Therapeutics Enters into Licensing Agreement with Cellectis
    • 7.1.2 Amgen and MD Anderson Enter Two Collaboration Agreements Across Various Cancer Types
    • 7.1.3 MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center

8 Appendix

  • About GlobalData
  • Contact Us
  • Disclaimer

List of Tables

  • Table 1: Definitions Used in TNM Classification and Clinical Staging System in Lung Cancer
  • Table 2: AJCC Staging of Lung Cancer
  • Table 3: SCLC Diagnosed Prevalent Cases (N), Thousands, 2014-2024

List of Figures

  • Figure 1: SCLC, Global Market by Molecular Target and Molecule Type, 2019
  • Figure 2: SCLC, Global, Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 3: SCLC, Global, Pipeline by Molecular Target and Stage of Development, 2019
  • Figure 4: SCLC, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 5: SCLC, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 6: SCLC, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 7: SCLC, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019